Scott M. Rocklage, Ph.D., is an executive in that invests in the pharmaceutical industry. He attended the University of California, Berkeley and graduated from there with a degree in chemistry. He then traveled across the country and attended the Massachusetts Institute of Technology, earning his Ph.D. in Chemistry.
When first entering the pharmaceutical industry. Dr. Rocklage worked as a researcher. He spent several years in a few company’s Research & Developments Departments including the firms Salutar and Catalytica.
His knowledge and experience eventually resulted in his earning top executive level positions at a number of pharmaceutical companies. He was named the CEO of Nycomed Salutar. He also was named by Cubist Pharmaceuticals as their Chairman and CEO.
In 2003, Dr. Scott Rocklage became an investor in the industry he knew so much about. He joined 5AM Ventures and the next year, in 2004, he was named as the firm’s Managing Partners. At 5AM Ventures, Dr. Rocklage and his partners invest in promising startups in the industry.
They are very involved, though, and don’t stop at just investing their money. They also provide their experience and knowledge so that the companies are successful in launching new and often life-saving drugs. Learn more about Dr. Scott Rocklage: http://5amventures.com/team/scott-m-rocklage-phd/ and https://ideamensch.com/scott-rocklage/
During his career, Dr. Rocklage has studied and written extensively. He has been the author of research papers that have been published in over 100 peer-reviewed medical journals. He also has either invented or co-invented a number of concepts and products and has more than 30 U.S. patents to his name.
As a leader in the industry, Dr. Rocklage serves in a number of board positions. This includes Relypsa, Achaogen, WaveRx, Variation, and Semprus. He also serves the Whitehead Institute on their Board of Associates. His central work location is in the city of Waltham, Massachusetts.